GB-0998

DRUG4 trials

Sponsors

Japan Blood Products Organization

Conditions

DermatomyositisEnd Stage Renal DiseaseGuillain-Barré SyndromePolymyositisRecurrent Miscarriage

Phase 2

The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.

CompletedNCT02032095

Japan Blood Products OrganizationEnd Stage Renal Disease

Start: 2013-11-30End: 2015-09-30Updated: 2016-02-05

Phase 3

Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)

CompletedNCT00335985

Japan Blood Products OrganizationDermatomyositis, Polymyositis

Start: 2006-06-30End: 2009-03-31Updated: 2014-11-05

A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage

CompletedNCT02184741

Japan Blood Products OrganizationRecurrent Miscarriage

Start: 2014-06-03End: 2020-09-30Updated: 2022-01-28

Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome

CompletedNCT02342184

Japan Blood Products OrganizationGuillain-Barré Syndrome

Start: 2014-08-31End: 2015-09-30Updated: 2016-02-04

Related Papers

Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses

EClinicalMedicine2022-08-26

Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial.

2022-06-2936 citations